Proteomics

Dataset Information

0

Effects of recombinant α1-microglobulin on early proteomic response in risk organs after exposure to 177Lu-octreotate


ABSTRACT: Introduction: Recombinant α1-microglobulin (A1M) is a proposed radioprotector during 177Lu-octreotate treatment of neuroendocrine tumors. Treatment with 177Lu-octreotate is currently limited by bone marrow and renal toxicity. Co-administration of 177Lu-octreotate and A1M could result in a more effective treatment by protecting healthy tissue while allowing higher absorbed doses to the tumor tissue. However, the mechanisms underlying the protective effects of co-administration of 177Lu-octreotate and A1M are still not fully understood. The aim of this study was to examine the proteomic response of mouse kidneys and bone marrow short time after 177Lu-octreotate and/or A1M administration. Methods: C57/6N mice (n=5/group) were injected with 150 MBq 177Lu-octreotate and/or A1M (5 mg/kg). Corresponding control mice (n=5/group) were injected with saline or the A1M vehicle solution. The animals were killed at 24 hours or 7 days post injection, followed by collection of bone marrow, kidney medulla, and kidney cortex samples at resp. time-points. One of the kidneys from each mouse was used for dosimetric assessment by measuring the 177Lu activity concentration in a gamma counter. Differential protein expression was analyzed with tandem mass spectrometry (LC-MS/MS). Ingenuity Pathway Analysis was then used to simulate affected canonical pathways, upstream regulators, and toxicity functions for identified proteins with |fold change| ≥ 1.5. Results: PHLDA3 was the most prominent radiation responsive protein found in kidney tissue. In general, no statistically significant difference in the expression of radiation-related proteins was observed between the 177Lu-octreotate and the 177Lu-octreotate+A1M groups. Several canonical pathways were identified in bone marrow, with the majority found in the 177Lu-octreotate+A1M group. Although toxicity functions related to nephrotoxicity were identified in kidney tissue in all groups, the predicted state (activated or inhibited) of these functions could not be determined. Conclusions: These findings demonstrated a tissue-dependent proteomic response following exposure to 177Lu-octreotate alone or together with A1M. Combining 177Lu-octreotate with A1M did not seem to inhibit the radiation induced expressions, short time after exposure. Long term effects of the combination of A1M and 177Lu-octreotate needs to be further studied.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Bone Marrow, Kidney

SUBMITTER: Proteomics Core Facility  

LAB HEAD: Carina Sihlbom

PROVIDER: PXD029937 | Pride | 2026-02-23

REPOSITORIES: Pride

altmetric image

Publications

Effects of Recombinant α<sub>1</sub>-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to <sup>177</sup>Lu-Octreotate.

Ytterbrink Charlotte C   Shubbar Emman E   Parris Toshima Z TZ   Langen Britta B   Druid Malin M   Schüler Emil E   Strand Sven-Erik SE   Åkerström Bo B   Gram Magnus M   Helou Khalil K   Forssell-Aronsson Eva E  

International journal of molecular sciences 20240708 13


Recombinant α<sub>1</sub>-microglobulin (A1M) is proposed as a protector during <sup>177</sup>Lu-octreotate treatment of neuroendocrine tumors, which is currently limited by bone marrow and renal toxicity. Co-administration of <sup>177</sup>Lu-octreotate and A1M could result in a more effective treatment by protecting healthy tissue, but the radioprotective action of A1M is not fully understood. The aim of this study was to examine the proteomic response of kidneys and bone marrow early after <s  ...[more]

Similar Datasets

2023-06-24 | GSE235292 | GEO
2024-09-18 | GSE267635 | GEO
2016-02-09 | E-GEOD-68878 | biostudies-arrayexpress
2022-05-30 | GSE204972 | GEO
2022-05-01 | GSE166129 | GEO
2025-07-31 | GSE300880 | GEO
2013-12-31 | E-GEOD-18490 | biostudies-arrayexpress
2025-04-01 | GSE292262 | GEO
2023-08-13 | PXD025837 | Pride
| PRJNA735243 | ENA